Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling ... In terms of achieving the highest alpha, owning the stock for two years may be the shrewdest ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly (NYSE:LLY) shares sold off on Tuesday ... Citing preliminary unaudited financials, LLY said that sales from its GLP-1 products, Mounjaro and Zepbound, indicated for diabetes and obesity ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...